DSM Biologics and Crucell Announce Licensing Agreement with Medarex

News

Published: December 20, 2007

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DSM Biologics and Crucell Announce Licensing Agreement with Medarex"

First Name*

Last Name*

Email Address*

Country*

Company Type*

Job Function*

Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

DSM Biologics and Dutch biotechnology company Crucell N.V. have announced a PER.C6® license agreement with biopharmaceutical company Medarex, Inc.

This license agreement allows Medarex to use the PER.C6® production platform in its antibody research. Financial details of the agreement were not disclosed.

Chosen for You